Shirley Wang

7.0k total citations · 2 hit papers
147 papers, 4.1k citations indexed

About

Shirley Wang is a scholar working on Economics and Econometrics, Statistics and Probability and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Shirley Wang has authored 147 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Economics and Econometrics, 46 papers in Statistics and Probability and 20 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Shirley Wang's work include Health Systems, Economic Evaluations, Quality of Life (42 papers), Statistical Methods in Clinical Trials (30 papers) and Advanced Causal Inference Techniques (30 papers). Shirley Wang is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (42 papers), Statistical Methods in Clinical Trials (30 papers) and Advanced Causal Inference Techniques (30 papers). Shirley Wang collaborates with scholars based in United States, Canada and United Kingdom. Shirley Wang's co-authors include Sebastian Schneeweiß, Joshua J. Gagne, Wim Goettsch, Marc L. Berger, C. Daniel Mullins, Rishi Desai, Richard J. Willke, Hans‐Georg Eichler, Thomas Evers and John B. Watkins and has published in prestigious journals such as Nature, JAMA and Journal of Biological Chemistry.

In The Last Decade

Shirley Wang

141 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)

2018 361 citations Sebastian Schneeweiß, Liam Smeeth et al. profile →
Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making

2017 327 citations Sebastian Schneeweiß, Shirley Wang et al. profile →

Peers

Countries citing papers authored by Shirley Wang

Since Specialization

Citations

This map shows the geographic impact of Shirley Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shirley Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shirley Wang more than expected).

Fields of papers citing papers by Shirley Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shirley Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shirley Wang. The network helps show where Shirley Wang may publish in the future.

Co-authorship network of co-authors of Shirley Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Shirley Wang. A scholar is included among the top collaborators of Shirley Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shirley Wang. Shirley Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice 2025 ·Nature Medicine ·(unknown), Sebastian Schneeweiß, Rishi Desai, Sushama Kattinakere Sreedhara, Anthony Kehoe, (unknown), Georg Hahn, Heribert Schunkert, Shirley Wang	1
2	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) 2024 ·Journal of Thoracic Oncology ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	0
3	Tree-based scan statistics to generate drug repurposing hypotheses: a test case using sodium-glucose cotransporter-2 inhibitors 2024 ·American Journal of Epidemiology ·(unknown), Judith C. Maro, Shirley Wang, Sengwee Toh, Jedidiah I Morton, Jenni Ilomäki, (unknown), Xiaojuan Li	0
4	FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004) 2024 ·Lung Cancer ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	2
5	Sharing Is Caring? International Society for Pharmacoepidemiology Review and Recommendations for Sharing Programming Code 2024 ·Pharmacoepidemiology and Drug Safety ·John Tazare, Shirley Wang, Rosa Gini, Daniel Prieto‐Alhambra, Peter Arlett, (unknown), Caroline E Morton, John Logie, Jennifer Popovic, Katherine Donegan, Sebastian Schneeweiß, Ian Douglas, Anna Schultze	2
6	Design differences and variation in results between randomised trials and non-randomised emulations: meta-analysis of RCT-DUPLICATE data 2024 ·SHILAP Revista de lepidopterología ·(unknown), Leonhard Held, Sebastian Schneeweiß, Shirley Wang	14
7	Comparison of EHR Data-Completeness in Patients with Different Types of Medical Insurance Coverage in the United States 2023 ·SSRN Electronic Journal ·(unknown), Yichi Zhang, (unknown), Yinzhu Jin, Shirley Wang, Joyce Lii, Jun S. Liu, Kueiyu Joshua Lin	2
8	Predicting Treatment Effects of a New‐to‐Market Drug in Clinical Practice Based on Phase III Randomized Trial Results 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), Shirley Wang, Dae Hyun Kim, (unknown), Mufaddal Mahesri, Lily G. Bessette, Sebastian Schneeweiß, Mehdi Najafzadeh	2
9	Stratified analysis in comparative effectiveness studies that emulate randomized trials 2023 ·Pharmacoepidemiology and Drug Safety ·(unknown), Robert J. Glynn, Shirley Wang, Julie M. Paik, Sebastian Schneeweiß, Alexander M. Walker, Elisabetta Patorno	4
10	Bringing the State-of-the-Art to Customers: A Neural Agent Assistant Framework for Customer Service Support 2022 ·(unknown), (unknown), Shirley Wang, (unknown), Elaine Lau, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
11	Understanding variation in the results of real-world evidence studies that seem to address the same question 2022 ·Journal of Clinical Epidemiology ·Shirley Wang, Sushama Kattinakere Sreedhara, Lily G. Bessette, Sebastian Schneeweiß	8
12	Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety 2022 ·JNCI Cancer Spectrum ·(unknown), Sebastian Schneeweiß, Sushama Kattinakere Sreedhara, Luke E. Zabotka, Kenneth Quinto, John Concato, Shirley Wang	5
13	Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting 2022 ·Pharmacoepidemiology and Drug Safety ·John Tazare, Richard Wyss, Jessica M. Franklin, Liam Smeeth, Stephen Evans, Shirley Wang, Sebastian Schneeweiß, Ian Douglas, Joshua J. Gagne, Elizabeth Williamson	16
14	Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting 2022 ·Pharmacoepidemiology and Drug Safety ·Nicolle M. Gatto, Shirley Wang, William Murk, (unknown), M. Alan Brookhart, Andrew Bate, Sebastian Schneeweiß, Jeremy A. Rassen	8
15	Carboxylic acids as anchoring components on aluminum oxide for the alignment relay technique of single-walled carbon nanotubes 2021 ·New Journal of Chemistry ·(unknown), Shirley Wang, (unknown), W. Scott Hopkins, Derek J. Schipper	1
16	A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes 2021 ·Endocrinology Diabetes & Metabolism ·Michael Fralick, Martin Kulldorff, Donald A. Redelmeier, Shirley Wang, Seanna Vine, Sebastian Schneeweiß, Elisabetta Patorno	6
17	<p>Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model</p> 2020 ·Clinical Epidemiology ·(unknown), Robert J. Glynn, Sebastian Schneeweiß, Kueiyu Joshua Lin, Elisabetta Patorno, Julie Barberio, Raisa Levin, Thomas Evers, Shirley Wang, Rishi Desai	27
18	Extension of Disease Risk Score–Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation 2018 ·American Journal of Epidemiology ·Rishi Desai, Richard Wyss, Yinzhu Jin, Justin Bohn, Sengwee Toh, (unknown), (unknown), Jessica Kim, (unknown), Rita Ouellet‐Hellstrom, Sara Karami, Jacqueline M. Major, (unknown), Shirley Wang, Joshua J. Gagne	8
19	Switching generic antiepileptic drug manufacturer not linked to seizures 2016 ·Neurology ·Aaron S. Kesselheim, Katsiaryna Bykov, Joshua J. Gagne, Shirley Wang, Niteesh K. Choudhry	32
20	Is Fatigue an Inflammatory Variable in Rheumatoid Arthritis (RA)? Analyses of Fatigue in RA, Osteoarthrits, and Fibromyalgia 2012 ·The Journal of Rheumatology ·Martin Bergman, (unknown), Timothy Shaver, James C. Anderson, David Weidensaul, (unknown), Shirley Wang, Frederick Wolfe, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact